Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.43 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 3/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3536008 | 1.00 | MBTD1 (0.43) | MBTD1L3MBTL3ACHEOPRD1CYP3A4 | |
| SCHEMBL10257602 | 0.81 | CHRNB2 (0.39) | ACHEOPRD1CYP3A4CYP2C9 | |
| SCHEMBL10257512 | 0.81 | CHRNB2 (0.39) | ACHEOPRD1CYP3A4CYP2C9 | |
| SCHEMBL4146221 | 0.76 | ACHE (0.36) | ACHEOPRD1CYP3A4 | |
| SCHEMBL3535779 | 0.74 | ACHE (0.41) | MBTD1L3MBTL3ACHECYP3A4CYP2C9 | |
| SCHEMBL3535777 | 0.74 | ACHE (0.41) | MBTD1L3MBTL3ACHECYP3A4CYP2C9 | |
| SCHEMBL4145997 | 0.74 | GAA (0.42) | ACHEOPRD1CYP3A4 | |
| SCHEMBL4146069 | 0.73 | GAA (0.44) | ACHEOPRD1CYP3A4 | |
| SCHEMBL3538646 | 0.73 | ACHE (0.34) | ACHEOPRD1CYP3A4 | |
| SCHEMBL4145688 | 0.73 | GAA (0.48) | ACHEOPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048224-A1 | COMPOUNDS AND METHODS OF USE | AMGEN, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-7425631-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-20050124654-A1 | Compounds and methods of use | AMGEN INC. | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124654-A1 | Compounds and methods of use | LTC4S, PTGES, LTB4R2 | MBTD1 4262/4885L3MBTL3 2540/4885ACHE 32/4885 |
| US-20090048224-A1 | COMPOUNDS AND METHODS OF USE | LTC4S, PTGES, LTB4R2 | MBTD1 4262/4885L3MBTL3 2540/4885ACHE 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.